Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Catheter Equipment

PUBLISHER: Grand View Research | PRODUCT CODE: 1750662

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1750662

U.S. Interventional Cardiology And Peripheral Market Size, Share & Trends Analysis Report By Product, By Application, And Segment Forecasts, 2025 - 2030

PUBLISHED:
PAGES: 160 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 4950
Printable PDF & Excel (5-User License)
USD 5950
Printable PDF & Excel (Enterprise License)
USD 7950

Add to Cart

Description

Table of Contents

List of Tables

U.S. Interventional Cardiology and Peripheral Market Growth & Trends:

The U.S. interventional cardiology and peripheral market size is anticipated to reach USD 11.19 billion by 2030, growing at a CAGR of 6.0% during the forecast period, according to a new report by Grand View Research, Inc. The market is driven by the growing burden of cardiovascular & peripheral vascular diseases, rising preference for minimally invasive procedures, and continuous advancements in device technology. Increasing geriatric population, higher rates of diabetes & hypertension, and supportive reimbursement policies further fuel market expansion.

The increasing incidence of cardiovascular conditions contributes to sustained growth in the interventional cardiology and peripheral market. A wide range of patients are being diagnosed with coronary and peripheral arterial blockages at various stages, prompting timely medical intervention. As disease detection improves through diagnostic advancements and routine check-ups, there is greater emphasis on early and less invasive treatment pathways.

Interventional procedures such as angioplasty, stenting, and thrombectomy are now central to managing these conditions effectively. In October 2024, the CDC reported that heart disease remained the leading cause of death in the U.S., responsible for 702,880 deaths in 2022, equivalent to one in every five deaths. Coronary artery disease (CAD) was the most common form, killing over 371,000 people. Risk factors such as high blood pressure, high cholesterol, smoking, diabetes, obesity, and physical inactivity were identified as major contributors.

U.S. Interventional Cardiology And Peripheral Market Report Highlights:

  • Based on product, the coronary stents segment accounted for the largest revenue share of 41.5% in 2024.
  • The segment growth is driven by increasing adoption of Percutaneous Coronary Interventions (PCI), continuous advancements in drug-eluting stent technologies, and favorable reimbursement policies supporting minimally invasive cardiovascular procedures in the U.S.
  • Based on application, the angioplasty segment accounted for the largest revenue share of 59.2% in 2024. The significant growth of this segment is largely driven by the high prevalence of atherosclerotic cardiovascular disease, increasing use of drug-eluting balloons & stents, and rising demand for minimally invasive revascularization procedures.
  • Emerging players are adopting diverse strategies, such as new product launches, to strengthen their market presence.
  • In February 2024, Biotronik launched the Micro Rx catheter in the U.S. to support guidewire procedures during PCI, reflecting ongoing technological progress and sustained market growth.
Show more
Product Code: GVR-4-68040-581-2

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Application
    • 1.2.3. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Application outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Interventional Cardiology and Peripheral Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. U.S. Interventional Cardiology and Peripheral Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. U.S. Interventional Cardiology and Peripheral Market: Product Estimates & Trend Analysis

  • 4.1. Product Segment Dashboard
  • 4.2. U.S. Interventional Cardiology and Peripheral Market: Product Movement Analysis
  • 4.3. U.S. Interventional Cardiology and Peripheral Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
  • 4.4. Interventional Catheters
    • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Microcatheters
    • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.2. Support Microcatheters
      • 4.5.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.3. Delivery Microcatheters
      • 4.5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.4. Others
      • 4.5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Guidewires
    • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Peripheral Stents
    • 4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.7.2. Self-Expanding
      • 4.7.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.7.3. Balloon-Expandable
      • 4.7.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.7.4. Drug-Eluting Stents
      • 4.7.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8. Coronary Stents
    • 4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.8.2. Bioabsorbable Stents
      • 4.8.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.8.3. Drug Eluting Stents
      • 4.8.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.8.4. Bare Metal Stents
      • 4.8.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.9. PTCA Balloon Catheters
    • 4.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.10. Atherectomy Devices
    • 4.10.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.11. Chronic Total Occlusion Devices
    • 4.11.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.12. Synthetic Surgical Grafts
    • 4.12.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.13. Embolic Protection Devices
    • 4.13.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.14. IVC Filters
    • 4.14.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.15. PTA Balloon Catheters
    • 4.15.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.16. Thrombectomy Devices
    • 4.16.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. Interventional Cardiology and Peripheral Market: Application Estimates & Trend Analysis

  • 5.1. Application Segment Dashboard
  • 5.2. U.S. Interventional Cardiology and Peripheral Market: Application Movement Analysis
  • 5.3. U.S. Interventional Cardiology and Peripheral Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 5.4. Angioplasty
    • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Congenital Heart Defect Correction
    • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Thrombectomy
    • 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. Valvuloplasty
    • 5.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8. Percutaneous Valve Repair
    • 5.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.9. Others
    • 5.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 6.2. Company/Competition Categorization
  • 6.3. Vendor Landscape
    • 6.3.1. Key company heat map analysis, 2024
  • 6.4. Company Profiles
    • 6.4.1. B. Braun SE
      • 6.4.1.1. Company overview
      • 6.4.1.2. Financial performance
      • 6.4.1.3. Product benchmarking
      • 6.4.1.4. Strategic initiatives
    • 6.4.2. BD
      • 6.4.2.1. Company overview
      • 6.4.2.2. Financial performance
      • 6.4.2.3. Product benchmarking
      • 6.4.2.4. Strategic initiatives
    • 6.4.3. Cardinal Health
      • 6.4.3.1. Company overview
      • 6.4.3.2. Financial performance
      • 6.4.3.3. Product benchmarking
      • 6.4.3.4. Strategic initiatives
    • 6.4.4. Medtronic
      • 6.4.4.1. Company overview
      • 6.4.4.2. Financial performance
      • 6.4.4.3. Product benchmarking
      • 6.4.4.4. Strategic initiatives
    • 6.4.5. Teleflex Incorporated
      • 6.4.5.1. Company overview
      • 6.4.5.2. Financial performance
      • 6.4.5.3. Product benchmarking
      • 6.4.5.4. Strategic initiatives
    • 6.4.6. W. L. Gore & Associates Inc.
      • 6.4.6.1. Company overview
      • 6.4.6.2. Financial performance
      • 6.4.6.3. Product benchmarking
      • 6.4.6.4. Strategic initiatives
    • 6.4.7. Cook
      • 6.4.7.1. Company overview
      • 6.4.7.2. Financial performance
      • 6.4.7.3. Product benchmarking
      • 6.4.7.4. Strategic initiatives
    • 6.4.8. Boston Scientific Corporation
      • 6.4.8.1. Company overview
      • 6.4.8.2. Financial performance
      • 6.4.8.3. Product benchmarking
      • 6.4.8.4. Strategic initiatives
    • 6.4.9. AngioDynamics
      • 6.4.9.1. Company overview
      • 6.4.9.2. Financial performance
      • 6.4.9.3. Product benchmarking
      • 6.4.9.4. Strategic initiatives
    • 6.4.10. Abbott
      • 6.4.10.1. Company overview
      • 6.4.10.2. Financial performance
      • 6.4.10.3. Product benchmarking
      • 6.4.10.4. Strategic initiatives
    • 6.4.11. OrbusNeich Medical Group Holdings Limited
      • 6.4.11.1. Company overview
      • 6.4.11.2. Financial performance
      • 6.4.11.3. Product benchmarking
      • 6.4.11.4. Strategic initiatives
Show more
Product Code: GVR-4-68040-581-2

List of Tables

  • Table 1 List of abbreviations
  • Table 2 U.S. interventional cardiology and peripheral market, by region, 2018 - 2030 (USD Million)
  • Table 3 U.S. interventional cardiology and peripheral market, by product, 2018 - 2030 (USD Million)
  • Table 4 U.S. interventional cardiology and peripheral market, by application, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 U.S. interventional cardiology and peripheral market: market outlook
  • Fig. 10 U.S. interventional cardiology and peripheral competitive insights
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Penetration and growth prospect mapping
  • Fig. 14 Industry value chain analysis
  • Fig. 15 U.S. interventional cardiology and peripheral market driver impact
  • Fig. 16 U.S. interventional cardiology and peripheral market restraint impact
  • Fig. 17 U.S. interventional cardiology and peripheral market strategic initiatives analysis
  • Fig. 18 U.S. interventional cardiology and peripheral market: Product movement analysis
  • Fig. 19 U.S. interventional cardiology and peripheral market: Product outlook and key takeaways
  • Fig. 20 Interventional catheters estimates and forecast, 2018 - 2030
  • Fig. 21 Microcatheters estimates and forecast, 2018 - 2030
  • Fig. 22 Support microcatheters estimates and forecast, 2018 - 2030
  • Fig. 23 Delivery microcatheters estimates and forecast, 2018 - 2030
  • Fig. 24 Others estimates and forecast, 2018 - 2030
  • Fig. 25 Guidewires estimates and forecast, 2018 - 2030
  • Fig. 26 Peripheral stents estimates and forecast, 2018 - 2030
  • Fig. 27 Self-expanding estimates and forecast, 2018 - 2030
  • Fig. 28 Balloon-expandable estimates and forecast, 2018 - 2030
  • Fig. 29 Drug-eluting stents estimates and forecast, 2018 - 2030
  • Fig. 30 Coronary stents estimates and forecast, 2018 - 2030
  • Fig. 31 Bioabsorbable stents estimates and forecast, 2018 - 2030
  • Fig. 32 Drug eluting stents estimates and forecast, 2018 - 2030
  • Fig. 33 Bare metal stents estimates and forecast, 2018 - 2030
  • Fig. 34 PTCA balloon catheters estimates and forecast, 2018 - 2030
  • Fig. 35 Atherectomy devices estimates and forecast, 2018 - 2030
  • Fig. 36 Chronic total occlusion devices estimates and forecast, 2018 - 2030
  • Fig. 37 Synthetic surgical grafts estimates and forecast, 2018 - 2030
  • Fig. 38 Embolic protection devices estimates and forecast, 2018 - 2030
  • Fig. 39 IVC filters estimates and forecast, 2018 - 2030
  • Fig. 40 PTA balloon catheters estimates and forecast, 2018 - 2030
  • Fig. 41 Thrombectomy devices estimates and forecast, 2018 - 2030
  • Fig. 42 U.S. interventional cardiology and peripheral market: Application movement analysis
  • Fig. 43 U.S. interventional cardiology and peripheral market: Application outlook and key takeaways
  • Fig. 44 Angioplasty estimates and forecast, 2018 - 2030
  • Fig. 45 Congenital heart defect correction estimates and forecast, 2018 - 2030
  • Fig. 46 Thrombectomy estimates and forecast, 2018 - 2030
  • Fig. 47 Valvuloplasty estimates and forecast, 2018 - 2030
  • Fig. 48 Percutaneous valve repair estimates and forecast, 2018 - 2030
  • Fig. 49 Others estimates and forecast, 2018 - 2030
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!